US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.34 against a street estimate of 0.27 — a beat of 25.9%.
Analysts rate Elanco Animal Health a buy (7 buy, 8 hold, 0 sell out of 15) with an average price target of $31.21.
CONFIDENT Elanco beat Q2 guidance on 8% organic growth driven by blockbuster innovation Zenrelia and Credelio Quattro. Raised full-year revenue and EPS guidance; approaching 3x net leverage. Strong derm and broad-spectrum parasiticide momentum offsets vet visit concerns. Q2 2026 U.S. pet health momentum accelerates despite vet visit concerns; management attributes growth to innovation and omnichannel behavior shift. International pet health leading with Zenrelia global expansion into 47 countries. Analysts probed pricing durability amid competition, Befrena supply/corporate timing, and Zenrelia runway. Management emphasized efficacy differentiation, data-driven DTC ROI, and international early innings. No label restriction concerns raised for Zenrelia despite new study commissioning. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Dodge & Cox | 13.49% |
| FMR Inc | 10.19% |
| BlackRock Inc | 9.53% |
| PRIMECAP Management Company | 9.10% |
| T. Rowe Price Investment Management,Inc. | 6.93% |
| Dimensional Fund Advisors, Inc. | 5.09% |
| Vanguard Portfolio Management, LLC | 4.53% |
| Vanguard Capital Management, LLC | 4.47% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ELANCO ANIMAL HEALTH INCORPORATED – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $1,368 million (Q2 2026) vs $1,241 million (Q2 2025) = 10.2% in | 2026-08-05 |
| Results announced · Q3 2026 ELANCO ANIMAL HEALTH – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1,368 million – up 10% reported, 8% organic constant currency g | 2026-08-05 |
| Shareholder vote results · Q2 2026 ELANCO ANIMAL HEALTH INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 21, 2026 • Total shares voted: approximately | 2026-05-27 |
| Quarterly report · Q1 2026 ELANCO ANIMAL HEALTH INCORPORATED – Q1 2026 SUMMARY HEADLINE NUMBERS • Revenue: $1,371 million (Q1 2026) vs. $1,193 million (Q1 2025) – increase of | 2026-05-06 |
| Results announced · Q2 2026 ELANCO ANIMAL HEALTH Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $1,371 million, up 15% year-over-year (10% organic constant currenc | 2026-05-06 |
| Proxy statement · Q4 2025 ELANCO ANIMAL HEALTH INC. — PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • CEO Jeff Simmons' total 2025 compensation: Not disclosed in th | 2026-04-08 |
| Annual report FY2025 ELANCO ANIMAL HEALTH INC - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Elanco Animal Health Incorporated (ticker: ELAN on NYSE) • | 2026-02-24 |
| Results announced · Q1 2026 ELANCO ANIMAL HEALTH — 2025 RESULTS & 2026 GUIDANCE SUMMARY HEADLINE NUMBERS • Q4 2025 Revenue: $1,144 million, up 12% reported / 9% organic constan | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Q2 2026 results and full year 2026 guidance provided Elanco Animal Health Incorporated filed an 8-K on August 5, 2026, announcing its Q2 2026 financial results (quarter ended June 30, 2026) and providing guidance for the remainder of 2026. The | 2026-08-05 |
| Q1 2026 results announced with full year and Q2 2026 guidance Elanco Animal Health Incorporated filed an 8-K on May 6, 2026, announcing Q1 2026 financial results for the quarter ended March 31, 2026, along with guidance for the full year 2026 and Q2 20 | 2026-05-06 |
| Full year 2025 results and 2026 guidance announced Elanco Animal Health Incorporated filed an 8-K on February 24, 2026, announcing its full-year 2025 financial results and fourth-quarter earnings. The company also provided forward guidance f | 2026-02-24 |
| Q3 2025 results and full year 2025 guidance announced Elanco Animal Health Incorporated filed an 8-K on November 5, 2025, announcing its third-quarter fiscal 2025 results (quarter ended September 30, 2025) and providing guidance for the full ye | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Elanco Animal Health — free to start.
Google PlayApp StoreData updated 2026-09-18.